Biocytogen Grants Taisho Pharmaceutical a License to its RenNano Fully Human Heavy ChainOnly Antibody Discovery Platform

Image for article Biocytogen Grants Taisho Pharmaceutical a License to its RenNano Fully Human Heavy ChainOnly Antibody Discovery Platform
News Source : Financial Post

News Summary

  • Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.
  • The company has entered into a platform license agreement with Taisho Pharmaceutical Co. Ltd. (“Taisho”) The agreement grants TaishO the right to access and use the company’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform.
BEIJING & TOKYO Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE 688796; HKEX 02315), a global biotechnology company that drives the research and development of novel antibodyba [+5689 chars]

Must read Articles